CurrentBlue Cross Blue Shield - IowaPolicy N/A

Measurement of Serum Antibodies to Selected Biologic Agents

This policy governs the use and coverage stance for laboratory testing that measures antidrug antibodies and drug levels for selected biologic agents used to treat inflammatory conditions; it affects providers ordering these tests and Blue Cross Blue Shield - Iowa members. (Partial document: initial sections and policy statement.)

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyMeasurement of Serum Antibodies to Selected Biologic Agents

Policy CodePolicy N/A

Change TypeAnnual review — no material changes

Effective DateJuly 2013

Next Review DateN/A

Key ActionDo not order routine antidrug‑antibody testing; consider testing selectively for patients with documented loss of response to biologic therapy and document prior management attempts.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2013-2026evidence timeframe

Numeroussystematic reviews

0-83%ADA rate (infliximab range)

12.4%maintenance infliximab ADA

84999

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

unlisted CPT referenced

Coverage Criteria and Evidence Summary

Investigational

Measurement of antidrug antibodies is considered investigational for the listed tests because evidence is insufficient to demonstrate improved net health outcomes.

Investigational tests: Measurement of antidrug antibodies in an individual receiving treatment with a biologic agent, either alone or as a combination test, including but not limited to the following assays: ADALX (Adalimumab Quantitative with Reflex to Antibody Serum Test), DoseASSURE ADL, DoseASSURE CTZ, DoseASSURE ETN, DoseASSURE GOL, DoseASSURE IFX, DoseASSURE UST, Prometheus Anser ADA, Prometheus Anser IFX, Prometheus Anser VDZ, and Prometheus Anser UST, is considered investigational.

See regulatory status and evidence summaries for rationale

Clinical Context and Test Purpose

Evidence review purpose and populations

PICO and evidence scope: Testing is intended to detect serum antibodies to biologic therapies (eg, infliximab and biosimilars, adalimumab and biosimilars, vedolizumab, golimumab, certolizumab, etanercept, ustekinumab and biosimilars) in individuals with inflammatory conditions including rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, moderate to severe plaque psoriasis, and inflammatory bowel disease (moderate to severe Crohn disease or ulcerative colitis); both pediatric and adult populations were considered in the review.

Technical reliability is outside the scope of the evidence review; focus is on clinical validity and utility

Evidence Summary

Summary of clinical validity evidence

Associations observed: Numerous systematic reviews and meta-analyses and multiple cohort studies have found that detectable antidrug antibodies (ADA) are associated with lower drug concentrations, reduced therapeutic response, and increased infusion- or injection-site reactions; concomitant immunosuppression (eg, methotrexate) is consistently associated with lower risk of ADA formation.

Magnitude of associations varies by drug, disease, and assay method; heterogeneity across studies limits comparability

General coverage stance

Evidence‑based stance summary

Overall clinical‑utility conclusion: Convincing evidence that routine measurement of ADAs and trough drug levels improves clinical outcomes is lacking; randomized trial data did not demonstrate improved remission with therapeutic drug monitoring (TDM) of infliximab (trough levels and ADA) compared with standard care, and retrospective/uncontrolled studies cannot confirm outcome benefit despite influencing management decisions.

Clinical utility inference limited by heterogeneous assays, transient antibodies, and study design limitations (eg, retrospective cohorts)

Algorithmic management in relapse

Situations where testing informed management in observational studies

Use in relapsed IBD patients: In observational cohorts of patients who relapse on anti‑TNF therapy, measurement of trough drug concentrations and ADA has been used to guide management decisions—options included dose escalation/interval shortening, addition of an immunomodulator, or switching to another biologic—with observational data suggesting these test results influenced subsequent therapy selection and outcomes in some cohorts.

Examples include Roblin et al (adalimumab optimization and switch to infliximab) and Afif et al (retrospective impact on infliximab management); however, these studies are nonrandomized and cannot establish improved net health outcomes

Testing limitations

Interpretation cautions

Test variability and transient antibodies: ADA can be transient—single measurements may be misleading—and assay methods differ in sensitivity and susceptibility to drug interference (eg, ELISA vs RIA vs HMSA), producing variable thresholds and complicating interpretation across studies; repeat testing and interpretation within the clinical context are recommended.

Reported median ADA concentrations and rates of transient positivity support caution when interpreting isolated results (eg, PANTS and Zitomersky findings)

Situations recommended by professional guidelines

Context for when testing may be appropriate according to guideline statements

Guideline-aligned indications: Professional guidelines suggest considering measurement of drug levels and antidrug antibodies primarily when a patient who initially responded to anti‑TNF therapy is losing response or when active disease is documented despite biologic therapy; routine proactive monitoring is not broadly recommended in all settings.

References include ACG (UC and CD guidance), AGA (TDM guidance), and NICE statements recommending data collection/research use in some indications

Empirical associations (not prescriptive criteria)

Evidence-based observations from studies

Findings relevant to coverage decisions: Empirical findings show ADAb positivity is associated with lower drug concentrations and reduced response across multiple biologics; specific reported thresholds vary by agent and study (eg, certolizumab serum levels ≥20 mg/L associated with response but >40 mg/L not associated with additional benefit), and background immunosuppression reduces immunogenicity.certolizumab >=20 mg/L (response), >40 mg/L (no added benefit)

Observational and registry data (NOR‑DMARD, Ramos, PANTS) illustrate interindividual variability and potential actionable thresholds, but require validation in randomized trials

Guideline-based management criteria

Guidance-based considerations

Management when trough sufficient: If trough concentrations are sufficient, antibody testing should not guide treatment decisions.trough sufficient

AGA guidance

Low trough, no antibodies: If the trough concentration is low and no anti‑drug antibodies are present, optimize the index drug by shortening the dosing interval and/or increasing the drug dose and/or adding an immunomodulator.low trough

AGA guidance

No detectable drug, high-titer antibodies: If there is no detectable drug (zero trough) and high‑titer anti‑drug antibodies are present, consider switching to a different drug within the class or to a different drug class.zero trough + high-titer antibodies

The policy identifies the following specific assays as investigational for measurement of antidrug antibodies: ADALX (Adalimumab Quantitative with Reflex to Antibody Serum Test), DoseASSURE™ ADL, DoseASSURE™ CTZ, DoseASSURE™ ETN, DoseASSURE™ GOL, DoseASSURE™ IFX, DoseASSURE™ UST, Prometheus® Anser® ADA, Prometheus® Anser® IFX, Prometheus® Anser® VDZ, and Prometheus® Anser® UST.

Technical reliability of assays is outside the scope of this evidence review and therefore is not assessed in the policy sections that determine clinical validity and utility.

An example from a cross-sectional cohort found 0% detectable ADA with etanercept, illustrating that ADA formation and its contribution to loss of response can differ by agent and that absence of ADA with a specific drug (etanercept in this cohort) limits the role of ADA testing for that agent in that population.

Overall, the evidence review concludes there is no convincing evidence that routine ADA testing improves clinical outcomes; routine, indiscriminate ADA measurement without a clear management plan is not supported by the cited evidence.

Evidence is limited by study design: many published reports are retrospective or observational (including post hoc analyses), and systematic reviewers have noted heterogeneity in assays and methods that restricts comparability and the ability to draw definitive conclusions.

The 2017 AGA guideline did not address therapeutic drug monitoring for vedolizumab or ustekinumab because of a paucity of data, reflecting limited evidence to inform testing and management for these agents.

Within the provided document excerpts there are no explicit determinations labeled as 'not medically necessary' for specific tests; the policy focuses on evidence review and investigational status for listed assays.

A randomized trial (Syversen et al.) found that proactive therapeutic drug monitoring of infliximab using trough levels and ADA did not improve clinical remission at prespecified timepoints compared with standard therapy without monitoring, so routine proactive TDM to prevent relapse has not been shown to improve remission outcomes.

Guidance and reviews (including NICE) indicate that routine ELISA-based therapeutic monitoring for TNF-α inhibitors in rheumatoid arthritis is not currently recommended for routine adoption; NICE advises that laboratories use such testing only within research or data-collection frameworks until evidence is sufficient.

NICE has stated there is insufficient evidence to recommend routine adoption of ELISA therapeutic monitoring tests for TNF‑alpha inhibitors in rheumatoid arthritis and recommends use of these tests within research or audit settings until more data are available.

Coding and Test Identifiers

Codes table referencedmixed

No codes listed

Assays and tests referenced (not billing codes)mixed

ADALX	Adalimumab Quantitative with Reflex to Antibody, Serum (Mayo Medical Laboratories)
DoseASSURE ADL	DoseASSURE TM ADL
DoseASSURE CTZ	DoseASSURE TM CTZ
DoseASSURE ETN	DoseASSURE TM ETN
DoseASSURE GOL	DoseASSURE TM GOL
DoseASSURE IFX	DoseASSURE TM IFX
DoseASSURE UST	DoseASSURE TM UST
Prometheus Anser ADA	Prometheus ® Anser ® ADA
Prometheus Anser IFX	Prometheus ® Anser ® IFX
Prometheus Anser VDZ	Prometheus ® Anser ® VDZ

1–10 of 11

1/2

Reported CPTCPT

84999

Unlisted chemistry procedure (when specified as Prometheus Anser IFX Testing, Prometheus Anser ADA, Prometheus Anser VDZ, or Prometheus Anser UST, DoseASSURE ADL, DoseASSURE GOL, DoseASSURE IFX, DoseASSURE UST or ADALX).

ADA prevalence ranges reported

Episodic infliximab ADA prevalence45.8% (Lee et al. 2012 pooled estimate for episodic infliximab)

Maintenance infliximab ADA prevalence12.4% (Lee et al. 2012 pooled estimate for maintenance infliximab)

Overall pooled ADA prevalence (meta-analysis)20.8% pooled ADA prevalence (Lee et al. 2012)

ADA discontinuation threshold / certolizumab therapeutic interval

ADA discontinuation threshold (Syversen trial)Antidrug antibodies ≥50 mcg/L — threshold reported as criterion for discontinuation in trial data

Proposed certolizumab therapeutic interval

Provider Instructions, Documentation, and Operational Notes

Prior Authorization

Prior Authorization and Benefit Verification

Prior approval for therapeutic drug monitoring (TDM) or antidrug antibody (ADAb) testing is not required by this policy; "PRIOR APPROVAL: Not applicable." Benefit coverage depends on the member's contract—verify member benefits prior to ordering. Although no payer prior‑authorization or step‑therapy rules are specified in the excerpt, providers should be aware that tests listed in the policy are considered investigational.

Prior approval: Not applicable.
Verify member benefits and contract-specific coverage before testing.

Documentation Required

Laboratory-Developed Tests and Commercial Assays

Laboratory‑developed tests (LDTs) used for measuring serum drug concentrations and antidrug antibodies must meet CLIA high‑complexity requirements and be performed in appropriately certified laboratories. Examples of commercial assays described in the policy include Prometheus Anser (HMSA) and DoseASSURE and ADALX (ELISA/RIA variants). Note that FDA regulatory review has not been required for these tests.

Background and Scope

Background: Biologic agents covered by this policy include infliximab, adalimumab, vedolizumab, ustekinumab, etanercept, golimumab, and certolizumab. These agents are used to treat multiple inflammatory conditions. Antidrug antibodies (ADA) can develop to these biologics and have been associated with lower drug concentrations, increased infusion or injection-site reactions, and secondary loss of response; however, the clinical value of measuring ADA depends on whether testing leads to management changes that improve patient outcomes, which current evidence has not convincingly demonstrated.

Definitions and Key Terms

Drug interference — Assay interference (ELISA vs HMSA)

Assay interference — ELISA limitationFirst‑generation assays (ELISA) can measure ADA only in the absence of detectable drug levels due to drug interference

HMSA advantageHomogeneous mobility shift assay (HMSA) can measure ADA in the presence of detectable drug, addressing a major ELISA limitation

RIA considerationsRadioimmunoassay (RIA) can measure ADA but has complexity, prolonged incubation, and safety concerns related to radioactive material

Laboratory‑developed test (LDT) — definition and CLIA requirement

LDT definitionLaboratory‑developed test (LDT): a clinical laboratory test developed and validated in‑house and offered as a service — LDTs must meet CLIA high‑complexity laboratory standards

Regulatory note

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyMeasurement of Serum Antibodies to Selected Biologic Agents

Policy CodePolicy N/A

Change TypeAnnual review — no material changes

Effective DateJuly 2013

Next Review DateN/A

Key ActionDo not order routine antidrug‑antibody testing; consider testing selectively for patients with documented loss of response to biologic therapy and document prior management attempts.

SourceLink

On This Page

No detectable drug, low-titer antibodies: If there is no detectable drug and low‑titer antibodies are present, consider optimizing the index drug (shorten interval/increase dose/add immunomodulator) before switching.zero trough + low-titer antibodies

AGA guidance

Use in rheumatoid arthritis (NICE): ELISA tests for therapeutic monitoring of TNF‑alpha inhibitors show promise but evidence is insufficient to recommend routine adoption in rheumatoid arthritis; laboratories should use such tests as part of research or prospective data collection.evidence insufficient

NICE guidance (2019)

Suggested CZP therapeutic serum interval for non‑trough samples: 20–40 mg/L (NOR‑DMARD and Ramos findings)

CZP levels and response relationshipCZP serum level ≥20 mg/L associated with treatment response; levels ≥40 mg/L showed no additional benefit

Adalimumab therapeutic trough example

Adalimumab therapeutic trough example>4.9 μg/mL (used by Roblin et al to define a therapeutic adalimumab level)

Use in grouping for management decisionsRoblin et al grouped patients by therapeutic (>4.9 μg/mL) vs subtherapeutic troughs to guide optimization or switching

Outcome relevanceGroups with subtherapeutic level but no antibodies achieved higher remission after optimization than those with therapeutic levels or with antibodies

Certolizumab serum therapeutic interval (non‑trough)

Certolizumab non‑trough therapeutic interval20–40 mg/L proposed therapeutic interval for non‑trough (serum) certolizumab samples

Interpretation caveatStudies note considerable inter‑individual variation and that therapeutic interval needs further validation in RCTs

Association with responseLevels ≥20 mg/L were associated with treatment response; >40 mg/L not associated with additional benefit

Golimumab trough level associated with long‑term remission (UC)

Golimumab week‑14 trough associated with long‑term remissionWeek 14 golimumab trough ~1.6 μg/mL associated with remission at 54 weeks (median [IQR] 1.6 μg/mL vs 0.9 μg/mL, p=0.043)

Timing of measurementTrough levels measured at weeks 6, 10, and 14; only week‑14 TL associated with 54‑week remission

Assay limitationAnti‑GLM antibody assay used could not detect antibodies in presence of drug (ELISA) — may limit interpretation

Trough concentration threshold (reference)

Reference to 'below suggested threshold' languageAGA guidance: 'If the trough concentration is low (below the suggested threshold, in patients with active IBD)...' — troughs described qualitatively when below suggested thresholds

Implication for managementLow trough (below suggested threshold) prompts optimization of index drug (shorten interval/increase dose/add immunomodulator)

Lack of uniform numeric thresholdsAGA notes uniform thresholds for clinically relevant antibody titers and troughs are lacking across assays

LDTs must be CLIA‑certified for high‑complexity testing.
Examples: Prometheus Anser IFX/ADA/VDZ/UST; DoseASSURE panels; ADALX (Mayo).

Documentation Required

Assay and Timing Documentation

Providers must document the assay method and timing of sample collection (eg, trough concentration vs routine/nontrough) when ordering and reporting TDM/ADAb testing. Studies and guidelines highlight differences in performance between assay methods (ELISA, RIA, HMSA) and the clinical interpretation is assay‑dependent; therefore documentation of method and timing supports appropriate clinical use and adjudication.

Document assay method (ELISA, RIA, HMSA, or proprietary platform) on the requisition or clinical note.
Document timing relative to dosing (trough vs nontrough).

Billing Rule

Assay Reporting and Coding

Coding and reporting for proprietary or unlisted assays should use appropriate CPT/HCPCS and diagnosis codes. When no specific CPT exists for the proprietary test, report as unlisted chemistry procedure CPT 84999 with an accompanying description indicating the assay (for example, Prometheus Anser IFX, Prometheus Anser ADA, DoseASSURE ADL, DoseASSURE IFX, ADALX). Use correct ICD‑10 diagnosis codes for the treated condition and follow payer billing guidance for laboratory services.

Report proprietary assays using CPT 84999 (Unlisted chemistry procedure) with test name specified.
Include ICD‑10 diagnosis code(s) for the indication when billing.
Follow payer-specific billing guidance for laboratory place/type of service.

Note

Operational Prior-Authorization / Denial Notes

No explicit prior‑authorization, denial triggers, or step‑therapy algorithms for TDM/ADAb testing are stated in the provided excerpts. The document focuses on evidence review, assay performance, and clinical contexts in which testing may inform management rather than on operational payer rules.

No payer prior authorization rules specified in excerpts.
No step‑therapy rules or explicit denial triggers described.

Note

Impact of Test Results on Clinical Management (Evidence)

Retrospective cohort studies and audits have reported that TDM/ADAb results frequently influenced clinical management decisions (eg, 73% of assessed tests impacted management in Afif et al; Vande Casteele reported persistence/nonpersistence of antibodies affecting discontinuation decisions). However, these are primarily retrospective or observational findings and may not establish improved health outcomes in randomized comparisons.

Afif et al (retrospective): test results impacted treatment decisions in ~73% of assessments.
Vande Casteele: persistent antibodies associated with infliximab discontinuation; some antibodies transient.
RCT evidence on improved clinical outcomes with TDM is limited.

Documentation Required

Algorithmic Management Based on TDM Results

Guidelines and trial-derived algorithms support algorithmic management based on trough drug concentrations and antibody status: - If trough concentrations are sufficient, antibody testing should not drive treatment changes. - If trough is low and no antibodies are present, optimize the index drug (shorten interval, increase dose, and/or add immunomodulator). - If no detectable drug and high‑titer antibodies are present, consider switching agents (within or between classes). - Low‑titer antibodies with undetectable drug may prompt optimization attempts before switching. Providers should note variability in assay sensitivity and lack of uniform antibody titer thresholds.

Optimize dosing (shorten interval/increase dose/add immunomodulator) when trough low and antibodies absent.
Switch to another agent when no detectable drug and high‑titer antibodies present.
Reporting variability and lack of standardized clinically relevant antibody titer thresholds may affect management.

Note

Comparators for Clinical Management

Clinical comparators used in studies and algorithms are standard‑of‑care management strategies (eg, dose intensification, switching biologics, or nonbiologic therapies). There is no prescribed step‑therapy algorithm for testing itself; management decisions are generally compared to usual care without TDM in trials.

Comparators in the literature: standard of care without TDM (eg, empiric dose escalation or switching).
No step‑therapy algorithm for testing was provided in the excerpts.

Documentation Required

Guideline-Based Operational Notes and Data Collection

Regulatory and guidance bodies (NICE, AGA, ACG) recommend selective or conditional use of TDM/ADAb testing—primarily for patients with loss of response on anti‑TNF therapy—and, in some settings (eg, RA per NICE), suggest testing be performed as part of research or further data collection. Document test indication and clinical context when ordering to support appropriate use and potential audit or registry reporting.

Guidelines generally recommend testing primarily for loss of response, not routine proactive monitoring (ACG/AGA conditional recommendations).
NICE recommends data collection/audit when using ELISA monitoring in RA.

FDA has not required regulatory review of these LDTs; laboratories offering LDTs must be CLIA‑licensed for high‑complexity testing

Commercial examplesCommercial HMSA‑based Anser tests (Prometheus) are offered by CLIA‑accredited labs as non‑ELISA assays capable of measuring ADA in presence of drug

Antidrug antibody (ADA) testing — definition and assay examples

ADA testing — definitionLaboratory assays (e.g., ELISA, HMSA, RIA) that detect antibodies directed against biologic therapies and may be performed alongside serum drug concentration measurements to inform management

Assay examplesCommon assay methods cited: ELISA (enzyme‑linked immunosorbent assay), RIA (radioimmunoassay), HMSA (homogenous mobility shift assay)

Commercial assays notedPrometheus Anser (HMSA) and DoseASSURE panels, and ADALX (Mayo) cited as available tests for drug and ADA measurement

Antidrug antibodies (ADA) — summary

ADA — summary of types and effectsAntidrug antibodies (binding and often neutralizing) develop variably across biologics and are associated with lower drug concentrations, reduced clinical response, and increased risk of infusion/injection reactions

Clinical associationsMeta‑analyses show ADA associated with reduced therapeutic response (RRs range across reviews) and increased adverse reaction risk (ORs ~2.07–3.25)

Persistence and clinical implicationsADAs can be transient; persistent high‑titer antibodies associated with drug discontinuation and may prompt switching

Trough level — definition and use

Trough level — definitionSerum drug concentration measured just prior to the next scheduled dose; used to correlate drug exposure with ADA presence and clinical response

Use in studiesTrough concentrations used in RCTs and cohort studies to guide optimization or switching decisions and to classify therapeutic vs subtherapeutic exposure

LimitationsTiming (true trough vs non‑trough) and assay heterogeneity affect comparability across studies

Antidrug antibodies — shorthand and examples

ADA shorthand and examplesAntidrug antibodies often abbreviated ADA or ADAb; drug‑specific shorthand examples include ATI (anti‑infliximab antibodies) and ATA (anti‑adalimumab antibodies)

Clinical measurement contextADA/ATI/ATA are reported alongside drug concentrations to interpret impact on efficacy and guide management

Assay variability noteReporting and terminology are variable between assays and studies, complicating uniform interpretation

Trough drug concentration (eg, certolizumab trough level) — definition

Trough drug concentration (definition)Trough drug concentration (eg, certolizumab trough level, CTL) — the measured serum concentration used to assess exposure, typically just before the next dose

Use for certolizumabCZP trough or serum levels have been used to associate exposure with clinical response and to define tentative therapeutic intervals

Interpretation caveatNon‑trough (random) serum samples were used in some studies; therapeutic intervals for non‑trough samples (e.g., 20–40 mg/L for CZP) are proposed with caution

Therapeutic drug monitoring (TDM) — definition and study variability

Therapeutic drug monitoring (TDM) — definitionMeasurement of serum drug concentrations and antidrug antibodies to guide management of biologic therapies; studies report variable assay methods, timing, and thresholds

Study variabilityRCTs and observational cohorts used different assays (ELISA, RIA, HMSA) and thresholds, limiting comparability and generalizability

Clinical applicationTDM has been used to guide dose escalation, addition of immunomodulator, or switching agents in loss‑of‑response scenarios, but RCT evidence of outcome benefit is limited

Anti‑drug antibody (ADAb) — definition and scope

Anti‑drug antibody (ADAb) — definitionHost immunologic response to biologic agents detectable by immunoassay, often neutralizing and associated with diminished clinical response and altered pharmacokinetics

Scope across agentsADAb rates vary widely across biologics (highest for infliximab and adalimumab in systematic reviews)

Clinical consequenceMost ADAbs reported in reviews were neutralizing except for abatacept and etanercept

Low trough concentration — definition used in guidance

Low trough concentration (policy definition)A drug serum trough level below suggested thresholds in patients with active disease, prompting optimization of the index drug (per AGA guidance)

Management implicationLow trough without antibodies → optimize index drug (shorten interval/increase dose/add immunomodulator); low trough with antibodies → interpretation less clear

Threshold ambiguityAGA notes that numeric 'suggested thresholds' are not uniform across assays and clinical contexts

High‑titer anti‑drug antibodies — definition and clinical implication

High‑titer anti‑drug antibodies — clinical implicationHigh‑titer ADAs, when associated with zero detectable drug (zero trough), suggest switching to a different drug within the class or to a different drug class

Persistence and actionPersistent high‑titer antibodies have been associated with discontinuation of the index drug in cohort studies

Reporting variabilityAssay sensitivity and reporting vary; high‑titer definitions differ between assays, limiting universal numeric cutoffs